AtriCure
ATRC
213 hedge funds and large institutions have $2.98B invested in AtriCure in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 69 increasing their positions, 84 reducing their positions, and 22 closing their positions.
24% more call options, than puts
Call options by funds: $1.87M | Put options by funds: $1.51M
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
0% more funds holding
Funds holding: 212 → 213 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.6% less ownership
Funds ownership: 97.11% → 94.51% (-2.6%)
15% less capital invested
Capital invested by funds: $3.49B → $2.98B (-$507M)
18% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 84
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.3M |
| 2 |
Millennium Management
New York
|
+$23.2M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$15.7M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.3M |
| 5 |
CA
CastleArk Alternatives
Chicago,
Illinois
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$46.9M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$26.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$25.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.9M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$11.1M |
ATRC Hedge Fund Activity: Q3 2021 in Review
213 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q3 2021, worth a combined $2.98B — down 15% from $3.49B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ATRC positions and 22 closed out — a net gain of 4 holders — while 69 added to existing stakes and 84 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $24.3M. The largest seller was Fidelity Investments, cutting an estimated $46.9M.
- 213 institutional investors held AtriCure (ATRC) as of Q3 2021, up from 212 in Q2 2021.
- Funds reported $2.98B of AtriCure stock for Q3 2021, down 15% quarter-over-quarter.
- 26 funds opened new AtriCure positions in Q3 2021 and 22 closed out, a net change of +4 holders.
- The largest AtriCure buyer in Q3 2021 was Balyasny Asset Management, an estimated $24.3M added.
- The largest AtriCure seller in Q3 2021 was Fidelity Investments, an estimated $46.9M sold.
Based on aggregated 13F filings for Q3 2021.